Class 2 recall-Sertraline 100mg tablets

Amarox Limited is recalling one batch of Sertraline 100 mg film-coated tablets as a precautionary measure due to an error at the manufacturing site.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-amarox-limited-sertraline-100mg-film-coated-tablets-el-26-a-slash-22?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2339f367-dda6-4275-90fc-0e7281517b0d&utm_content=immediately

MHRA drug alert date: 28/04/26

Further Information

For all medical information enquiries, information and for reporting of side effects please email Safety@Amaroxpharma.com or telephone +44 2039720005 and for stock control enquiries please email info@amaroxpharma.com or telephone +44 2039720002.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Napralief 9s

Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing text in Section 2 and Section 3 of the Patient Information Leaflet (PIL) and on the Carton in packs of Napralief 250mg Gastro-resistant tablets.

MHRA drug alert link: Class 3 Medicines Recall: Omega Pharma Ltd, Napralief 250mg Gastro-Resistant Tablets, EL(26)A/21 - GOV.UK

MHRA drug alert date:23/04/26

Further Information

For all medical information enquiries, stock control queries and information on this product, please email UKLOcustomerservice@perrigo.com or call +44 0203 598 9603.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-PI Hiprex 1g tablets

Doncaster Pharma Limited has informed the MHRA of an error related to the Braille embossing on the outer packaging of certain parallel imported batches of Hiprex 1 g tablets (POM).

MHRA drug alert Date: 26/3/26

MHRA drug alert link: Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email regulatory@doncasterpharma.co.uk or quality.enquiries@doncasterpharma.co.uk, or telephone 01302 365 000.

For stock control enquiries, please email commercial@doncasterpharma.co.uk, or telephone 01302 365 000.

Class 2 recall-Ramipril 10mg Caps

Crescent Pharma Limited is recalling one batch of Ramipril 10mg Capsules as a precautionary measure due to a potential error at the manufacturing site.

MHRA drug alert link: Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 10mg capsules, EL(26)A/19 - GOV.UK

MHRA drug alert date:20/04/26

Further Information

For all medical information enquiries and information, please email medinfo@crescentpharma.com, for reporting of side effects email safety@crescentpharma.com or telephone +44 1217901596 and for stock control enquiries please email complaints@crescentpharma.com

Class 2 recall-Human normal Immunoglobulin 500IU solution for Injection

Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin following a stability failure for this batch. The batch has shown a reduction in potency of the Human Rabies immunoglobulin.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bio-products-laboratory-limited-rabies-human-normal-immunoglobulin-500iu-solution-for-injection-el-26-a-slash-18

MHRA drug alert date:30/03/26

Further Information

For all medical information enquiries and information on this product, please email medinfo@bpl.co.uk  or medinfo@kedrion.com or telephone +44 (0)20 89572255, +44 (0)20 89572622 or +44 (0)20 89572200

For stock control enquiries please email bplorders@kedrion.com, or telephone +44 (0)20 89572251

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Apixaban 2.5mg and 5mg Tablets

Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information.

MHRA drug alert Date: 26/3/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email mi.uk@sandoz.com, or telephone +44 1276 698101.

For stock control enquiries please email sales.sandoz-gb@sandoz.com, or telephone +44 1276 698020.

Class 4 caution in use- PI Vesomni 6 mg/0.4 mg modified release tablets

Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton.

MHRA drug alert Date: 26/3/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Quadrant Pharmaceuticals Limited, Vesomni 6 mg/0.4 mg modified release tablets , EL(26)A/16 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email maxearnqa@maxearn.co.uk or telephone 01204 471269.

For stock control enquiries please email maxearnqa@maxearn.co.uk or telephone 01204 471269.

Class 2 recall-Hibiwash 500ml

Mölnlycke Health Care are recalling specific batches of Hibiwash due to microbial contamination at the manufacturing facility, following routine weekly microbiological monitoring.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-regent-medical-limited-slash-molnlycke-health-care-hibiwash-500ml-el-26-a-slash-15?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=090ab6cb-237a-4a04-a47b-b9e8dcf71bae&utm_content=immediately

MHRA drug alert date:23/03/26

Further Information

For medical information enquiries please use contact: Vigilance@molnlycke.com or telephone: +46 31 722 30 00. For stock queries please contact: UK Responsible Person: mohammad.humadi@molnlycke.com  

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to

Class 4 caution in use-Onkotrone Injection 2 mg/ml concentrate for solution for infusion

Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in specified batches does not contain up to date information relating to the duration of contraception required for females after stopping taking this medication.

MHRA drug alert Date: 17/3/26

MHRA drug alert link:Class 4 Medicines Defect Notification: Baxter Healthcare Corporation, Onkotrone Injection 2 mg/ml concentrate for solution for infusion, EL(26)A/14 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries regarding this communication, contact Baxter at MedInfo_UKI@baxter.com or telephone 0800 0260516

For stock control enquiries please contact Baxter at servicecs@baxter.com or telephone 0800 028 9881

Class 2 recall-Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml)

Curaleaf Laboratories are recalling three batches of Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml) due to low THC content.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-rokshaw-limited-trading-as-curaleaf-laboratories-curaleaf-oil-fs-10mg-slash-ml-thc-10mg-slash-ml-cbd-30ml-el-26-a-slash-13?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=b93a959c-5bc7-4b1e-9fa2-503ce10856ac&utm_content=immediately

MHRA drug alert date:12/03/26

Further Information

For all medical information enquiries and information on this product, please email orders@curaleaflaboratories.co.uk, or telephone +44 0191 7431007.

For stock control enquiries please email orders@curaleaflaboratories.co.uk,  or telephone +44 0191 7431007.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.